Common Stock $0.00001 per share
- Symbol
- SHPH
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 7.01, 9.01 · 8-K
Shuttle Pharmaceuticals Holdings, Inc.
SHPHNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 6, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Company context
Shuttle Pharma is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. Our goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (“radiation therapy” or “RT”) is one of the most effective modalities for treating cancers. We are developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. We believe that our product candidates will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Current securities
Registered securities in this filing
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. · 8-K · Filed 2026-03-10
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On
March 6, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is
filed as Exhibit 99.1 to this Current Report on Form 8-K.
Filed exhibits (2)
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. PRE-FUNDED WARRANT Warrant Initial Shares: [ ] Exercise Date: [_______], 2026 Issue Date: [_______], 2026 THIS PRE-FUNDED WARRANT (the “ Warrant ”) certifies that, for value received, [_______] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “ Initial Exercise Date ”) and until this Warrant is exercised in full (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “ Company ”), up to [_____] shares of Common Stock (as subject to adjustment hereunder, the “ Warrant Shares ”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “ Purchase Agreement ”), dated [ ], 2026, …
Open exhibit ↗EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Shuttle Pharmaceuticals Announces $3.5 Million Public Offering GAITHERSBURG, Md., March 6, 2026 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), the owner of Molecule.ai, an artificial intelligence (“AI”) driven platform for molecular discovery and early-stage drug development, today announced that it has entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common stock, in a public offering, for aggregate gross proceeds of approximately $3,500,000, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions. E.F. Hutton & Co. is acting as the exclusive placement agent for the offering. The Company intends to use up to $1.5 million of the net proceeds from this offering for future marketing efforts and the remainder for working capital and general corporate purposes. The securities described above are being offered and sold by the Company in…
Open exhibit ↗